Molecular structure of Adenosine Kinase Inhibitor, CAS Number: 214697-26-4
Adenosine Kinase Inhibitor Inhibitor (CAS 214697-26-4)
See product citations (9)
Alternate Names:
ABT-702; 4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine
Application:
Adenosine Kinase Inhibitor is a cell-permeable compound that acts as a potent adenosine kinase inhibitor
CAS Number:
214697-26-4
Purity:
≥90%
Molecular Weight:
536.3
Molecular Formula:
C22H19BrN6O•2HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Adenosine Kinase Inhibitor is a cell-permeable, non-nucleoside pyridopyrimidine compound that acts as a potent, adenosine-competitive, and reversible ADK (adenosine kinase (AK)) inhibitor (IC50 = 50.7 nM using intact IMR-32 cells and 1.7 nM in cell-free assays using rat brain cytosolic AK). The inhibitory effect is not species-specific and its pharmacological selectivity is confirmed using a panel of more than 80 other enzymes, ion channels, and receptors, including various adesine receptors.
Adenosine Kinase Inhibitor Inhibitor (CAS 214697-26-4) References
- ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. | Jarvis, MF., et al. 2000. J Pharmacol Exp Ther. 295: 1156-64. PMID: 11082453
- ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. | Kowaluk, EA., et al. 2000. J Pharmacol Exp Ther. 295: 1165-74. PMID: 11082454
- Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. | Boyle, DL., et al. 2001. J Pharmacol Exp Ther. 296: 495-500. PMID: 11160636
- The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury. | Suzuki, R., et al. 2001. Br J Pharmacol. 132: 1615-23. PMID: 11264257
- The adenosine kinase inhibitor ABT-702 augments EEG slow waves in rats. | Radek, RJ., et al. 2004. Brain Res. 1026: 74-83. PMID: 15476699
- 4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors. | Matulenko, MA., et al. 2007. Bioorg Med Chem. 15: 1586-605. PMID: 17197188
- ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. | Elsherbiny, NM., et al. 2013. Life Sci. 93: 78-88. PMID: 23770229
- Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy. | Ahmad, S., et al. 2014. J Neuroimmunol. 277: 96-104. PMID: 25457840
- An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat. | Otsuguro, K., et al. 2015. Neuropharmacology. 97: 160-70. PMID: 26066576
- Clearance of rapid adenosine release is regulated by nucleoside transporters and metabolism. | Nguyen, MD., et al. 2015. Pharmacol Res Perspect. 3: e00189. PMID: 27022463
- Adenosine kinase inhibition protects against cisplatin-induced nephrotoxicity. | Cao, W., et al. 2019. Am J Physiol Renal Physiol. 317: F107-F115. PMID: 30995110
- Adenosine Kinase Inhibition Augments Conducted Vasodilation and Prevents Left Ventricle Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction. | Davila, A., et al. 2019. Circ Heart Fail. 12: e005762. PMID: 31525084
- Inhibition of adenosine kinase attenuates myocardial ischaemia/reperfusion injury. | Wang, W., et al. 2021. J Cell Mol Med. 25: 2931-2943. PMID: 33523568
- Adenosine kinase (ADK) inhibition with ABT-702 induces ADK protein degradation and a distinct form of sustained cardioprotection. | Wölkart, G., et al. 2022. Eur J Pharmacol. 927: 175050. PMID: 35618039
Inhibitor of:
ADK, and PKAβ cat.Activator of:
P2Y1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Adenosine Kinase Inhibitor, 5 mg | sc-202900 | 5 mg | $443.00 |